search
BioNTech
Trends
- 1
BioNTech is under pressure on two fronts in Germany. The company's works council has publicly criticised toxic working conditions and internal shortcomings at the biotech firm. At the same time, BioNTech reported an update on its mRNA cancer immunotherapy candidate BNT113 for HPV16-positive metastatic head and neck cancer, which commentators describe as the latest setback for the company's oncology programme.
- 2Ontario pharmacies expand COVID vaccine options●Update for Ontario: Many pharmacies in Ontario now offer the Sanofi Nuvaxovid and Pfizer-BioNTech Comirnaty vaccines — i
Many pharmacies across Ontario are now offering the Sanofi Nuvaxovid and Pfizer-BioNTech Comirnaty COVID-19 vaccines, adding to the made-in-Canada Moderna Spikevax that has been widely available since the start of the 2026-2027 vaccination program. Residents are being encouraged to check local pharmacy availability and consider which vaccine option suits them as the season's immunization campaign continues.
- 3Penn-BioNTech $50M fund backs first startup Emvena▼$50M Penn-BioNTech fund backs first startup, Emvena
A $50 million fund created by the University of Pennsylvania and BioNTech has made its first investment, backing the startup Emvena. The fund is designed to support early-stage life sciences ventures emerging from Penn research, and Emvena marks its debut deal. Details on Emvena's technology and funding amount have not yet been widely reported.
- 4
BioNTech founders Uğur Şahin and Özlem Türeci have been honored with a science award, according to Hürriyet Daily News. The couple, who developed one of the first COVID-19 vaccines, continue to be recognized internationally for their contributions to medical research. No further details about the award or ceremony were provided in the initial report.